BIOHAVEN LTD (BHVN)

VGG1110E1079 - Common Stock

35.91  -0.35 (-0.97%)

News Image
7 days ago - Biohaven Ltd.

Biohaven Reports Positive Phase 1 Degrader Data, Achieving Deep Targeted IgG Reductions in the Lowest Subcutaneous Dose Tested; Announces NDA Submission for Troriluzole in SCA and Provides Other Key Program Updates

BHV-1300 achieved deep lowering of targeted IgG, with reductions > 60% in the lowest subcutaneous dose tested in the MAD. Subcutaneous BHV-1300 achieved rapid...

News Image
17 days ago - Biohaven Ltd.

Biohaven Presents New Data with BHV-7000 Once-Daily Extended-Release Formulation Demonstrating Excellent Safety Profile and Nonclinical Data Updates at American Epilepsy Society 2024 Annual Meeting

Reported expanded safety results from BHV-7000 Phase 1 multiple ascending dose studies, including the once-daily extended-release formulation being evaluated...

News Image
a month ago - Biohaven Ltd.

Biohaven Provides Update on Taldefgrobep Alfa Development Program for Spinal Muscular Atrophy and Obesity

In the RESILIENT SMA study, taldefgrobep alpha showed clinically meaningful improvements in motor function at all timepoints on the Motor Function...

News Image
a month ago - Market News Video

BHVN January 2027 Options Begin Trading

News Image
a month ago - Biohaven Ltd.

Biohaven Reports Third Quarter 2024 Financial Results and Recent Business Developments

Cash, cash equivalents, marketable securities and restricted cash as of October 2, 2024 totaled approximately $642 million Achieved positive topline trial...

News Image
2 months ago - Market News Video

Notable Friday Option Activity: BHVN, GETY, AFRM

News Image
3 months ago - Investor's Business Daily

Scholar Rock Catapults By Triple Digits On Final-Phase Win In Spinal Muscular Atrophy

The company is hoping to treat patients with spinal muscular atrophy, a muscle-wasting disease.

News Image
3 months ago - Biohaven Ltd.

Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

/PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...

News Image
3 months ago - Biohaven Ltd.

Biohaven Announces Pricing of $250 Million Public Offering of Common Shares

/PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN),a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...

News Image
3 months ago - Biohaven Ltd.

Biohaven Announces Proposed Public Offering of Common Shares

/PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...

News Image
3 months ago - Biohaven Ltd.

Biohaven Initiates Pivotal Trial of Novel Investigational Drug for Treatment of Migraine

Biohaven initiated a pivotal Phase 2 trial evaluating BHV-2100 in the acute treatment of migraine BHV-2100 is a potential first-in-class, potent, orally...

News Image
3 months ago - Market News Video

Wednesday 9/25 Insider Buying Report: PMN, BHVN

News Image
3 months ago - Market News Video

BHVN Crosses Above Key Moving Average Level

News Image
3 months ago - Investor's Business Daily

Biohaven Surges After Delaying Progression By Up To 70% In A Rare Disease

The company is hoping to soon file for approval of what could be the first SCA treatment.

News Image
3 months ago - Biohaven Ltd.

Biohaven Achieves Positive Topline Results in Pivotal Study of Troriluzole in Spinocerebellar Ataxia (SCA)

Troriluzole 200 mg dosed orally, once daily, in patients with SCA met the study's primary endpoint on the change from baseline in the modified functional Scale...

News Image
3 months ago - Biohaven Ltd.

Biohaven Announces Conference Call to Discuss Topline Pivotal Study Results in Spinocerebellar Ataxia

/PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) (Biohaven), today announced that it will host a conference call to discuss topline data from Study BHV4157-206-RWE...

News Image
3 months ago - Market News Video

Notable Thursday Option Activity: NOV, BHVN, SIG